Vivimed Labs Ltd (VIVIMEDLAB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Vivimed Labs Ltd (VIVIMEDLAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013346
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vivimed Labs Ltd (Vivimed) is a supplier of niche molecules and formulations to healthcare, pharmaceuticals and specialty chemicals customers across the world. The company provides active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals. It manufactures and supplies APIs for hair, skin, oral care; and anti-microbial preservatives for home and personal care market. The company offers contract manufacturing services and the manufacture of branded formulations. It offers a comprehensive range of hair dye intermediates for permanent, semi-permanent and temporary hair coloring, photo chromic dyes, and imaging chemicals. It has presence in India, China, Mauritius, the UK, the US, Spain, and Mexico. Vivimed is headquartered in Hyderabad, Telangana, India.

Vivimed Labs Ltd (VIVIMEDLAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vivimed Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Vivimed Labs Acquires Solid Oral Dosage Facility From Actavis Pharma For US$20 Million 10
Private Equity 11
OrbiMed Asia Partners to Invest USD42.5 Million in Uquifa 11
Kitara Capital to Acquire Additional Stake in Vivimed Labs for USD2.6 Million 12
NYLIM Jacob And Kitara Invest US$27.5 Million In Vivimed Labs 13
Partnerships 14
Strides Shasun to Form Joint Venture with Vivimed Labs 14
CritiTech Enters Into Joint Venture With Finoso Pharma 15
Debt Offering 16
Vivimed Labs Completes Private Placement Of Foreign Currency Convertible Bonds For US$7.5 Million 16
Acquisition 17
Vivimed Labs Acquires Finoso Pharma For US$3 Million 17
Vivimed Completes Acquisition Of Uquifa For US$55 Million 18
Vivimed Labs Acquires Ophthalmology Company Klar Sehen 20
Vivimed Labs Acquires 60% Stake In Octtantis Nobel Labs 21
Vivimed Labs Ltd – Key Competitors 22
Vivimed Labs Ltd – Key Employees 23
Vivimed Labs Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 26
Legal and Regulatory 26
Sep 21, 2017: Vivimeds FDF Facility In Jeedimetla Obtained Ukraine GMP Approval 26
Jun 06, 2017: Vivimed Labs Provides Update on USFDA Inspection at UQUIFA’s Facility 27
Nov 29, 2016: Vivimed’s FDF facllity in Alathur completed successful USFDA inspection 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vivimed Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vivimed Labs Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Vivimed Labs Acquires Solid Oral Dosage Facility From Actavis Pharma For US$20 Million 10
OrbiMed Asia Partners to Invest USD42.5 Million in Uquifa 11
Kitara Capital to Acquire Additional Stake in Vivimed Labs for USD2.6 Million 12
NYLIM Jacob And Kitara Invest US$27.5 Million In Vivimed Labs 13
Strides Shasun to Form Joint Venture with Vivimed Labs 14
CritiTech Enters Into Joint Venture With Finoso Pharma 15
Vivimed Labs Completes Private Placement Of Foreign Currency Convertible Bonds For US$7.5 Million 16
Vivimed Labs Acquires Finoso Pharma For US$3 Million 17
Vivimed Completes Acquisition Of Uquifa For US$55 Million 18
Vivimed Labs Acquires Ophthalmology Company Klar Sehen 20
Vivimed Labs Acquires 60% Stake In Octtantis Nobel Labs 21
Vivimed Labs Ltd, Key Competitors 22
Vivimed Labs Ltd, Key Employees 23
Vivimed Labs Ltd, Other Locations 24
Vivimed Labs Ltd, Subsidiaries 24

★海外企業調査レポート[Vivimed Labs Ltd (VIVIMEDLAB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Actron Manufacturing, Inc.:企業の戦略・SWOT・財務情報
    Actron Manufacturing, Inc. - Strategy, SWOT and Corporate Finance Report Summary Actron Manufacturing, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Greif Inc (GEF):企業の財務・戦略的SWOT分析
    Greif Inc (GEF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Shaheen Insurance Company Limited:企業の戦略・SWOT・財務情報
    Shaheen Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary Shaheen Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Ferring International Center SA-製薬・医療分野:企業M&A・提携分析
    Summary Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (foll …
  • Kura Oncology Inc (KURA)-製薬・医療分野:企業M&A・提携分析
    Summary Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company which discovers and develops therapeutics for the treatment of solid tumors and blood cancers. Its lead drug candidate, Tipifarnib, an inhibitor of protein farnesylation, is a small molecule that targets oncogene …
  • Merz Pharma GmbH & Co. KGaA:企業のM&A・事業提携・投資動向
    Merz Pharma GmbH & Co. KGaA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merz Pharma GmbH & Co. KGaA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Oriental Land Co., Ltd. (4661):企業の財務・戦略的SWOT分析
    Oriental Land Co., Ltd. (4661) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Shenzhen Neptunus Interlong Bio-Technique Co Ltd (8329):企業の財務・戦略的SWOT分析
    Summary Shenzhen Neptunus Interlong Bio-Technique Co Ltd (Neptunus) manufactures and distributes gene engineering drugs and preventive biological products. The company’s products include recombinant human interferon a-2b injection, used to treat hepatitis and cancers; recombinant human interleukin-2 …
  • Banco BPI SA:企業の戦略・SWOT・財務分析
    Banco BPI SA - Strategy, SWOT and Corporate Finance Report Summary Banco BPI SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Leidos Biomedical Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary Leidos Biomedical Research Inc (Leidos), formerly SAIC-Frederick Inc, a subsidiary of Leidos Holdings Inc is a biomedical research center that develops therapies. The center offers operations and technical support services. It provides research and maintenance programs in areas of genetics, …
  • MI Bioresearch Inc-医療機器分野:企業M&A・提携分析
    Summary MI Bioresearch Inc (MI), formerly Molecular Imaging Inc is a research institute that offers pharmacology research services. The institute offers services such as oncology pharmacology, immuno oncology, in vitro services, imaging and radiation. Its oncology pharmacology include subcutaneous m …
  • QT Vascular Ltd (5I0):医療機器:M&Aディール及び事業提携情報
    Summary QT Vascular Ltd (QT Vascular) is a medical device manufacturing company that offers developing, manufacturing and distributing of advanced therapeutic solutions for the treatment of complex vascular diseases. The company’s products include coronary products such as Chocolate PTCA Balloon Cat …
  • Capture Vascular Inc:医療機器:M&Aディール及び事業提携情報
    Summary Capture Vascular Inc (Capture Vascular) is a medical device development company that develops and commercializes mechanical thrombectomy systems. The company offers MegaVac, a mechanical thrombectomy system that removes clots in arteries and provides vessel occlusion, embolic prevention and …
  • BioSolar Inc (BSRC):企業の財務・戦略的SWOT分析
    Summary BioSolar Inc (BioSolar) is an alternative energy technology company that develops storage capacity products. The company develops technology to produce bio-based materials from renewable sources. BioSolar products include biosolar back-sheets, biosolar thin film substrate, biosolar super-str …
  • Molex LLC-医療機器分野:企業M&A・提携分析
    Summary Molex LLC (Molex), a subsidiary of Koch Industries, is a US-based manufacturer of electronic components. The company principally focuses on manufacturing and sale of electronic, electrical and fiber optic interconnection systems. Molex's product portfolio includes switches, integrated produc …
  • Reliance Nippon Life Insurance Company Limited:企業の戦略・SWOT・財務情報
    Reliance Nippon Life Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Nippon Life Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Hanwha Corp (000880):企業の財務・戦略的SWOT分析
    Hanwha Corp (000880) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The TJX Companies, Inc. (TJX):企業の財務・戦略的SWOT分析
    The TJX Companies, Inc. (TJX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Stena Metall AB:企業の戦略・SWOT・財務分析
    Stena Metall AB - Strategy, SWOT and Corporate Finance Report Summary Stena Metall AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Camber Energy, Inc. (CEI)-石油・ガス分野:企業M&A・提携分析
    Summary Camber Energy, Inc. (Camber Energy) formerly known as Lucas Energy, Inc. is an independent oil and gas company. It explores, develops, and produces crude oil, natural gas and natural gas liquids (NGL). The company has asset base in Texas and Oklahoma. Camber Energy’s oil and gas reserves are …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆